DNA Damage Response Pathways and Cancer

Abeloff's Clinical Oncology: Fifth Edition

Volumn , Issue , 2013, Pages 142-153.e4

  Ford, James M ^a   Kastan, Michael B ^b,c  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE CANCER INSTITUTE   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84944592317     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4557-2865-7.00010-2     Document Type: Chapter

References (192)

1. Sjoblom T, Jones S, Wood LD, et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006, 314:268-274.
2. Gray J, Druker B Genomics: the breast cancer landscape. Nature 2012, 486:328-329.
3. Cancer Genome Atlas Network Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012, 487:330-337.
4. Loeb LA, Loeb KR, Anderson JP Multiple mutations and cancer. Proc Natl Acad Sci U S A 2003, 100:776-781.
5. Loeb LA, Bielas JH, Beckman RA Cancers exhibit a mutator phenotype: clinical implications. Cancer Res 2008, 68:3551-3557.
6. Bodmer W, Bielas JH, Beckman RA Genetic instability is not a requirement for tumor development. Cancer Res 2008, 68:3558-3560.
7. Ciccia A, Elledge SJ The DNA damage response: making it safe to play with knives. Mol Cell 2010, 40:179-204.
8. Hoeijmakers JH DNA damage, aging, and cancer. N Engl J Med 2009, 361:1475-1485.
9. Ford JM, Hanawalt PC Role of DNA excision repair gene defects in the etiology of cancer. Curr Top Microbiol Immunol 1997, 221:47-70.
10. Bohr VA, Smith CA, Okumoto DS, Hanawalt PC DNA repair in an active gene: removal of pyrimidine dimers from the DHFR gene of CHO cells is much more efficient than in the genome overall. Cell 1985, 40:359-369.
11. Mellon I, Bohr VA, Smith CA, Hanawalt PC Preferential DNA repair of an active gene in human cells. Proc Natl Acad Sci U S A 1986, 83:8878-8882.
12. Mellon I, Spivak G, Hanawalt PC Selective removal of transcription-blocking DNA damage from the transcribed strand of the mammalian DHFR gene. Cell 1987, 51:241-249.
13. Yamaizumi M, Sugano T U.v.-induced nuclear accumulation of p53 is evoked through DNA damage of actively transcribed genes independent of the cell cycle. Oncogene 1994, 9:2775-2784.
14. Ljungman M, Zhang F Blockage of RNA polymerase as a possible trigger for UV light-induced apoptosis. Oncogene 1996, 13:823-831.
15. Nelson WG, Kastan MB DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol Cell Biol 1994, 14:1815-1823.
16. Ljungman M, Lane DP Transcription - guarding the genome by sensing DNA damage. Nat Rev Cancer 2004, 4:727-737.
17. Friedberg EC, Wagner R, Radman M Specialized DNA polymerases, cellular survival, and the genesis of mutations. Science 2002, 296:1627-1630.
18. Kunkel TA Considering the cancer consequences of altered DNA polymerase function. Cancer Cell 2003, 3:105-110.
19. Sale JE, Lehmann AR, Woodgate R Y-family DNA polymerases and their role in tolerance of cellular DNA damage. Nat Rev Mol Cell Biol 2012, 13:141-152.
20. Hartwell LH, Kastan MB Cell cycle control and cancer. Science 1994, 266:1821-1828.
21. Ford JM, Hanawalt PC Li-Fraumeni syndrome fibroblasts homozygous for p53 mutations are deficient in global DNA repair but exhibit normal transcription-coupled repair and enhanced UV resistance. Proc Natl Acad Sci U S A 1995, 92:8876-8880.
22. Ford JM, Hanawalt PC Expression of wild-type p53 is required for efficient global genomic nucleotide excision repair in UV-irradiated human fibroblasts. J Biol Chem 1997, 272:28073-28080.
23. Hwang BJ, Ford JM, Hanawalt PC, Chu G Expression of the p48 xeroderma pigmentosum gene is p53-dependent and is involved in global genomic repair. Proc Natl Acad Sci, USA 1999, 96:424-428.
24. Adimoolam S, Ford JM p53 and DNA damage-inducible expression of the xeroderma pigmentosum group C gene. Proc Natl Acad Sci U S A 2002, 19:12985-12990.
25. Adimoolam S, Ford JM p53 and regulation of DNA damage recognition during nucleotide excision repair. DNA Repair (Amst) 2003, 2:947-954.
26. Scully R, Chen J, Ochs RL, et al. Dynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA damage. Cell 1997, 90:425-435.
27. Scully R, Chen J, Plug A, et al. Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell 1997, 88:265-275.
28. Cortez D, Wang Y, Qin J, Elledge SJ Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks. Science 1999, 286:1162-1166.
29. Wu X, Ranganathan V, Weisman DS, et al. ATM phosphorylation of Nijmegen breakage syndrome protein is required in a DNA damage response. Nature 2000, 405:477-482.
30. Fitch ME, Cross IV, Ford JM p53 responsive nucleotide excision repair gene products p48 and XPC, but not p53, localize to sites of UV-irradiation-induced DNA damage, in vivo. Carcinogenesis 2003, 24:843-850.
31. Fitch ME, Nakajima S, Yasui A, Ford JM In vivo recruitment of XPC to UV-induced cyclobutane pyrimidine dimers by the DDB2 gene product. J Biol Chem 2003, 278:46906-46910.
32. Smith ML, Fornace AJ Mammalian DNA damage-inducible genes associated with growth arrest and apoptosis. Mutat Res 1996, 340:109-124.
33. Fornace AJ, Amundson SA, Bittner M, et al. The complexity of radiation stress responses: analysis by informatics and functional genomics approaches. Gene Expr 1999, 7:387-400.
34. Hastak K, Adimoolam S, Trinklein ND, et al. Identification of a Functional In Vivo p53 Response Element in the Coding Sequence of the Xeroderma Pigmentosum Group C Gene. Genes & Cancer 2012, 2:1-10.
35. Lowe SW, Schmitt EM, Smith SW, et al. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 1993, 362:847-849.
36. Lowe SW, Ruley HE, Jacks T, Housman DE p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993, 74:957-967.
37. Clarke AR, Purdie CA, Harrison DJ, et al. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 1993, 362:849-852.
38. Hanahan D, Weinberg RA Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
39. Cline SD, Hanawalt PC Who's on first in the cellular response to DNA damage?. Nat Rev Mol Cell Biol 2003, 4:361-373.
40. Canman CE, Lim DS, Cimprich KA, et al. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science 1998, 281:1677-1679.
41. Kastan MB, Lim DS The many substrates and functions of ATM. Nat Rev Mol Cell Biol 2000, 1:179-186.
42. Shieh SY, Ahn J, Tamai K, Taya Y, Prives C The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. Genes Dev 2000, 14:289-300.
43. Matsuoka S, Huang M, Elledge SJ Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. Science 1998, 282:1893-1897.
44. Liu Q, Guntuku S, Cui XS, et al. Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. Genes Dev 2000, 14:1448-1459.
45. Shiloh Y ATM and related protein kinases: safeguarding genome integrity. Nat Rev Cancer 2003, 3:155-168.
46. Tibbetts RS, Brumbaugh KM, Williams JM, et al. A role for ATR in the DNA damage-induced phosphorylation of p53. Genes Dev 1999, 13:152-157.
47. Xu B, O'Donnell AH, Kim ST, Kastan MB Phosphorylation of serine 1387 in Brca1 is specifically required for the Atm-mediated S-phase checkpoint after ionizing irradiation. Cancer Res 2002, 62:4588-4591.
48. Bakkenist CJ, Kastan MB DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 2003, 421:499-506.
49. Hanawalt PC Subpathways of nucleotide excision repair and their regulation. Oncogene 2002, 21:8949-8956.
50. Ford JM Regulation of DNA damage recognition and nucleotide excision repair: another role for p53. Mutat Res 2005, 577:195-202.
51. Friedberg EC DNA Repair 1985, W.H. Freeman and Co., New York.
52. Setlow RB, Carrier W The disappearance of thymidine dimers from DNA: an error correcting mechanism. Proc Natl Acad Sci USA 1964, 51:226-231.
53. Boyce R, Howard-Flanders P Release of UV light-induced thymidine dimers from DNA in E. coli. Proc Natl Acad Sci, USA 1964, 51:293-300.
54. Pettijohn D, Hanawalt PC Evidence for repair-replication of UV damage in bacteria. J Mol Biol 1964, 9:395-402.
55. Wood RD Nucleotide excision repair in mammalian cells. J Biol Chem 1997, 272:23465-23468.
56. de Laat WL, Jaspers NG, Hoeijmakers JH Molecular mechanism of nucleotide excision repair. Genes Dev 1999, 13:768-785.
57. Wood RD, Mitchell M, Sgouros J, Lindahl T Human DNA repair genes. Science 2001, 291:1284-1289.
58. Cleaver JE, Lam ET, Revet I Disorders of nucleotide excision repair: the genetic and molecular basis of heterogeneity. Nat Rev Genet 2009, 10:756-768.
59. Hartman AR, Ford JM BRCA1 induces DNA damage recognition factors and enhances nucleotide excision repair. Nat Genet 2002, 32:180-184.
60. Lin PS, McPherson LA, Chen AY, Sage J, Ford JM The role of the retinoblastoma/E2F1 tumor suppressor pathway in the lesion recognition step of nucleotide excision repair. DNA Repair (Amst) 2009, 8:795-802.
61. Alli E, Sharma VB, Hartman AR, et al. Enhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cells. BMC pharmacology 2011, 11:7.
62. Huang TT, D'Andrea AD Regulation of DNA repair by ubiquitylation. Nat Rev Mol Cell Biol 2006, 7:323-334.
63. Masutani C, Kusumoto R, Yamada A, et al. The XPV (xeroderma pigmentosum variant) gene encodes human DNA polymerase eta. Nature 1999, 399:700-704.
64. Johnson RE, Kondratick CM, Prakash S, Prakash L hRAD30 mutations in the variant form of xeroderma pigmentosum. Science 1999, 285:263-265.
65. Cleaver JE Defective repair replication of DNA in xeroderma pigmentosum. Nature 1968, 218:652-656.
66. Kraemer KH, Lee MM, Scotto J DNA repair protects against cutaneous and internal neoplasia: evidence from xeroderma pigmentosum. Carcinogenesis 1984, 5:511-514.
67. Cleaver JE, Kraemer KH Xeroderma pigmentosum. Metabolic basis of inherited disease 1989, 2949-2971. McGraw-Hill, New York. C.R. Scriver, A.L. Beudet, W.S. Sly, D. Valle (Eds.).
68. Kraemer KH, Slor H Xeroderma Pigmentosum. Clinics in Dermatology 1985, 3:33-69.
69. Robbins JH Xeroderma pigmentosum: defective DNA repair causes skin cancer and neurodegeneration. JAMA: the journal of the American Medical Association 1988, 260:384-388.
70. Wang YC, Maher VM, Mitchell DL, McCormick JJ Evidence from mutation spectra that the UV hypermutability of xeroderma pigmentosum variant cells reflects abnormal, error-prone replication on a template containing photoproducts. Mol Cell Biol 1993, 13:4276-4283.
71. Schmickel RD, Chu EHY, Trosko JE Cockayne syndrome: a cellular sensitivity to ultraviolet light. Pediatrics 1977, 60:135-139.
72. Venema J, Mullenders LHF, Natarajan AT, et al. The genetic defect in Cockayne syndrome is associated with a defect in repair of UV-induced DNA damage in transcriptionally active DNA. Proc Natl Acad Sci U S A 1990, 87:4707-4711.
73. Cooper PK, Nouspikel T, Clarkson SG, Leadon SA Defective transcription-coupled repair of oxidative base damage in Cockayne syndrome patients from XP group G. Science 1997, 275:990-993.
74. Timme TL, Moses RE Review: diseases with DNA damage-processing defects. Am J Med Sci 1988, 295:40-48.
75. Nance MA, Berry SA Cockayne Syndrome: review of 140 cases. Am J Med Gen 1992, 42:68-84.
76. Robbins JH, Kraemer KH, Lutzner MA, et al. Xeroderma pigmentosum: an inherited disease with sun sensitivity, multiple cutaneous neoplasms and abnormal repair. Ann Intern Med 1974, 80:221-228.
77. Vermeulen W, Scott RJ, Rodgers S, et al. Clinical heterogeneity within xeroderma pigmentosum associated with mutations in the DNA repair and trasncription gene ERCC3. Am J Hum Genet 1994, 54:191-200.
78. Lehmann AR The xeroderma pigmentosum group D (XPD) gene: one gene, two functions, three diseases. Genes Dev 2001, 15:15-23.
79. Sarasin A UVSSA and USP7: new players regulating transcription-coupled nucleotide excision repair in human cells. Genome medicine 2012, 4:44.
80. Demple B, Harrison L Repair of oxidative damage to DNA: enzymology and biology. Annu Rev Biochem 1994, 63:915-948.
81. Seeberg E, Eide L, Bjoras M The base excision repair pathway. Trends Biochem Sci 1995, 20:391-397.
82. Al-Tassan N, Chmiel NH, Maynard J, et al. Inherited variants of MYH associated with somatic G:C->T:A mutations in colorectal tumors. Nat Genet 2002, 30:227-232.
83. Jones S, Emmerson P, Maynard J, et al. Biallelic germline mutations in MYH predispose to multiple colorectal adenoma and somatic G:C->T:A mutations. Hum Mol Genet 2002, 11:2961-2967.
84. Halford SE, Rowan AJ, Lipton L, et al. Germline Mutations but Not Somatic Changes at the MYH Locus Contribute to the Pathogenesis of Unselected Colorectal Cancers. Am J Pathol 2003, 162:1545-1548.
85. Cheadle JP, Sampson JR MUTYH-associated polyposis-from defect in base excision repair to clinical genetic testing. DNA Repair (Amst) 2007, 6:274-279.
86. Le Page F, Kwoh EE, Avrutskaya A, et al. Transcription-coupled repair of 8-oxoguanine: requirement for XPG, TFIIH, and CSB and implications for Cockayne syndrome. Cell 2000, 101:159-171.
87. Bohr VA Repair of oxidative DNA damage in nuclear and mitochondrial DNA, and some changes with aging in mammalian cells. Free Radic Biol Med 2002, 32:804-812.
88. Morland I, Rolseth V, Luna L, et al. Human DNA glycosylases of the bacterial Fpg/MutM superfamily: an alternative pathway for the repair of 8-oxoguanine and other oxidation products in DNA. Nucleic Acids Res 2002, 30:4926-4936.
89. Friedberg EC, Meira LB Database of mouse strains carrying targeted mutations in genes affecting biological responses to DNA damage. Version 5. DNA Repair (Amst) 2003, 2:501-530.
90. Goodenberger M, Lindor NM Lynch syndrome and MYH-associated polyposis: review and testing strategy. J Clin Gastroenterol 2011, 45:488-500.
91. Kiyohara C, Takayama K, Nakanishi Y Association of genetic polymorphisms in the base excision repair pathway with lung cancer risk: a meta-analysis. Lung Cancer 2006, 54:267-283.
92. Hung RJ, Hall J, Brennan P, Boffetta P Genetic polymorphisms in the base excision repair pathway and cancer risk: a HuGE review. Am J Epidemiol 2005, 162:925-942.
93. Loeb LA, Springgate CF, Battula N Errors in DNA replication as a basis of malignant changes. Cancer Res 1974, 34:2311-2321.
94. Loeb LA Mutator phenotype may be required for multistage carcinogenesis. Cancer Res 1991, 51:3075-3079.
95. Mohrenweiser HW, Wilson DM, Jones IM Challenges and complexities in estimating both the functional impact and the disease risk associated with the extensive genetic variation in human DNA repair genes. Mutat Res 2003, 526:93-125.
96. Simonelli V, Mazzei F, D'Errico M, Dogliotti E Gene susceptibility to oxidative damage: from single nucleotide polymorphisms to function. Mutat Res 2012, 731:1-13.
97. Fearnhead NS, Wilding JL, Winney B, et al. Multiple rare variants in different genes account for multifactorial inherited susceptibility to colorectal adenomas. Proc Natl Acad Sci U S A 2004, 101:15992-15997.
98. Fearnhead NS, Winney B, Bodmer WF Rare variant hypothesis for multifactorial inheritance: susceptibility to colorectal adenomas as a model. Cell Cycle 2005, 4:521-525.
99. Bodmer W, Bonilla C Common and rare variants in multifactorial susceptibility to common diseases. Nat Genet 2008, 40:695-701.
100. Wang L, Wei Q, Shi Q, et al. A modified host-cell reactivation assay to measure repair of alkylating DNA damage for assessing risk of lung adenocarcinoma. Carcinogenesis 2007, 28:1430-1436.
101. Lippman SM, Klein EA, Goodman PJ, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2009, 301:39-51.
102. Kolodner R Biochemistry and genetics of eukaryotic mismatch repair. Genes Dev 1996, 10:1433-1442.
103. Kolodner RD, Marsischky GT Eukaryotic DNA mismatch repair. Curr Opin Genet Dev 1999, 9:89-96.
104. Jiricny J, Nystrom-Lahti M Mismatch repair defects in cancer. Curr Opin Genet Dev 2000, 10:157-161.
105. Peltomaki P Role of DNA mismatch repair defects in the pathogenesis of human cancer. J Clin Oncol 2003, 21:1174-1179.
106. Fishel R, Lescoe MK, Rao MRS, et al. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 1993, 75:1027-1038.
107. Hemminki A, Peltomaki P, Mecklin JP, et al. Loss of the wild type MLH1 gene is a feature of hereditary nonpolyposis colorectal cancer. Nat Genet 1994, 8:405-410.
108. Papadopoulos N, Nicolaides NC, Wei YF, et al. Mutation of a mutL homolog in hereditary colon cancer. Science 1994, 263:1625-1629.
109. Karran P, Bignami M DNA damage tolerance, mismatch repair and genome instability. Bioessays 1994, 16:833-839.
110. Lynch HT, Smyrk T Hereditary nonpolyposis colorectal cancer (Lynch syndrome). An updated review. Cancer 1996, 78:1149-1167.
111. Lynch HT, de la Chapelle A Hereditary colorectal cancer. N Engl J Med 2003, 348:919-932.
112. Parsons R, Li GM, Longley MJ, et al. Hypermutability and mismatch repair deficiency in RER+ tumor cells. Cell 1993, 75:1227-1236.
113. Thibodeau SN, Bren G, Schaid D Microsatellite instability in cancer of the proximal colon. Science 1993, 260:816-819.
114. Kuismanen SA, Holmberg MT, Salovaara R, et al. Epigenetic phenotypes distinguish microsatellite-stable and -unstable colorectal cancers. Proc Natl Acad Sci U S A 1999, 96:12661-12666.
115. Nakagawa H, Nuovo GJ, Zervos EE, et al. Age-related hypermethylation of the 5' region of MLH1 in normal colonic mucosa is associated with microsatellite-unstable colorectal cancer development. Cancer Res 2001, 61:6991-6995.
116. Ford JM, Whittemore AS Predicting and preventing hereditary colorectal cancer. JAMA: the journal of the American Medical Association 2006, 296:1521-1523.
117. Gryfe R, Kim H, Hsieh ET, et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 2000, 342:69-77.
118. Hemminki A, Mecklin JP, Jarvinen H, et al. Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy. Gastroenterology 2000, 119:921-928.
119. Samowitz WS, Curtin K, Ma KN, et al. Microsatellite instability in sporadic colon cancer is associated with an improved prognosis at the population level. Cancer Epidemiol Biomarkers Prev 2001, 10:917-923.
120. Ji H, Kumm J, Zhang M, et al. Molecular inversion probe analysis of gene copy alterations reveals distinct categories of colorectal carcinoma. Cancer Res 2006, 66:7910-7919.
121. Hampel H, Frankel WL, Martin E, et al. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol 2008, 26:5783-5788.
122. Ladabaum U, Wang G, Terdiman J, et al. Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis. Ann Intern Med 2011, 155:69-79.
123. Bell DW, Varley JM, Szydlo TE, et al. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science 1999, 286:2528-2531.
124. Meijers-Heijboer H, van den Ouweland A, Klijn J, et al. Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 2002, 31:55-59.
125. Vahteristo P, Bartkova J, Eerola H, et al. A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. Am J Hum Genet 2002, 71:432-438.
126. Kastan MB, Onyekwere O, Sidransky D, et al. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991, 51:6304-6311.
127. Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci U S A 1992, 89:7491-7495.
128. Khanna KK, Keating KE, Kozlov S, et al. ATM associates with and phosphorylates p53: mapping the region of interaction. Nat Genet 1998, 20:398-400.
129. Banin S, Moyal L, Shieh S, et al. Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 1998, 281:1674-1677.
130. O'Driscoll M, Jeggo PA The role of double-strand break repair-insights from human genetics. Nat Rev Genet 2006, 7:45-54.
131. Gatti RA, Tward A, Concannon P Cancer risk in ATM heterozygotes: a model of phenotypic and mechanistic differences between missense and truncating mutations. Mol Genet Metab 1999, 68:419-423.
132. Dork T, Bendix R, Bremer M, et al. Spectrum of ATM gene mutations in a hospital-based series of unselected breast cancer patients. Cancer Res 2001, 61:7608-7615.
133. Scott SP, Bendix R, Chen P, et al. Missense mutations but not allelic variants alter the function of ATM by dominant interference in patients with breast cancer. Proc Natl Acad Sci U S A 2002, 99:925-930.
134. Carney JP, Maser RS, Olivares H, et al. The hMre11/hRad50 protein complex and Nijmegen breakage syndrome: linkage of double-strand break repair to the cellular DNA damage response. Cell 1998, 93:477-486.
135. Stewart GS, Maser RS, Stankovic T, et al. The DNA double-strand break repair gene hMRE11 is mutated in individuals with an ataxia-telangiectasia-like disorder. Cell 1999, 99:577-587.
136. Schneider JG, Finck BN, Ren J, et al. ATM-dependent suppression of stress signaling reduces vascular disease in metabolic syndrome. Cell Metab 2006, 4:377-389.
137. Valentin-Vega YA, Maclean KH, Tait-Mulder J, et al. Mitochondrial dysfunction in ataxia-telangiectasia. Blood 2012, 119:1490-1500.
138. Nakayama H, Nakayama K, Nakayama R, et al. Isolation and genetic characterization of a thymineless death-resistant mutant of Escherichia coli K12: identification of a new mutation (recQ1) that blocks the RecF recombination pathway. Mol Gen Genet 1984, 195:474-480.
139. Hickson ID RecQ helicases: caretakers of the genome. Nat Rev Cancer 2003, 3:169-178.
140. Ellis NA, Groden J, Ye TZ, et al. The Bloom's syndrome gene product is homologous to RecQ helicases. Cell 1995, 83:655-666.
141. Ellis NA, German J Molecular genetics of Bloom's syndrome. Hum Mol Genet 1996, 5:1457-1463.
142. Gruber SB, Ellis NA, Scott KK, et al. BLM heterozygosity and the risk of colorectal cancer. Science 2002, 297:2013.
143. Goss KH, Risinger MA, Kordich JJ, et al. Enhanced tumor formation in mice heterozygous for Blm mutation. Science 2002, 297:2051-2053.
144. Yu CE, Oshima J, Fu YH, et al. Positional cloning of the Werner's syndrome gene. Science 1996, 272:258-262.
145. Oshima J The Werner syndrome protein: an update. Bioessays 2000, 22:894-901.
146. Shen JC, Loeb LA The Werner syndrome gene: the molecular basis of RecQ helicase-deficiency diseases. Trends Genet 2000, 16:213-220.
147. Kitao S, Shimamoto A, Goto M, et al. Mutations in RECQL4 cause a subset of cases of Rothmund-Thomson syndrome. Nat Genet 1999, 22:82-84.
148. Wang LL, Gannavarapu A, Kozinetz CA, et al. Association between osteosarcoma and deleterious mutations in the RECQL4 gene in Rothmund-Thomson syndrome. J Natl Cancer Inst 2003, 95:669-674.
149. Hollstein M, Sidranksky D, Vogelstein B, Harris CC p53 mutations in human cancers. Science 1991, 253:49-53.
150. Kastan MB, Radin AI, Kuerbitz SJ, et al. Levels of p53 protein increase with maturation in human hematopoietic cells. Cancer Res 1991, 51:4279-4286.
151. Kastan MB, Zhan Q, El-Deiry WS, et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 1992, 71:587-597.
152. Sengupta S, Harris CC p53: traffic cop at the crossroads of DNA repair and recombination. Nat Rev Mol Cell Biol 2005, 6:44-55.
153. Oren M Regulation of the p53 tumor suppressor protein. J Biol Chem 1999, 274:36031-36034.
154. El-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993, 75:817-825.
155. Vousden KH, Lu X Live or let die: the cell's response to p53. Nat Rev Cancer 2002, 2:594-604.
156. Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas and other neoplasms. Science 1990, 250:1233-1238.
157. Srivastava S, Zou ZQ, Pirollo K, Blattner W, Chang EH Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature 1990, 348:747-749.
158. Frebourg T, Barbier N, Yan YX, et al. Germ-line p53 mutations in 15 families with Li-Fraumeni syndrome. Am J Hum Genet 1995, 56:608-615.
159. Jasin M Homologous repair of DNA damage and tumorigenesis: the BRCA connection. Oncogene 2002, 21:8981-8993.
160. Venkitaraman AR Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 2002, 108:171-182.
161. Venkitaraman AR A growing network of cancer-susceptibility genes. N Engl J Med 2003, 348:1917-1919.
162. Zhang J, Powell SN The role of the BRCA1 tumor suppressor in DNA double-strand break repair. Mol Cancer Res 2005, 3:531-539.
163. Alli E, Sharma VB, Sunderesakumar P, Ford JM Defective repair of oxidative DNA damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase. Cancer Res 2009, 69:3589-3596.
164. Xu B, Kim S, Kastan MB Involvement of Brca1 in S-phase and G(2)-phase checkpoints after ionizing irradiation. Mol Cell Biol 2001, 21:3445-3450.
165. Wang Y, Cortez D, Yazdi P, et al. BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures. Genes Dev 2000, 14:927-939.
166. Moynahan ME, Chiu JW, Koller BH, Jasin M Brca1 controls homology-directed DNA repair. Mol Cell 1999, 4:511-518.
167. Roy R, Chun J, Powell SN BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nat Rev Cancer 2012, 12:68-78.
168. Harkin DP, Bean JM, Miklos D, et al. Induction of GADD45 and JNK/SAPK-dependent apoptosis following inducible expression of BRCA1. Cell 1999, 97:575-586.
169. Hastak K, Alli E, Ford JM Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin. Cancer Res 2010, 70:7970-7980.
170. Saha T, Rih JK, Roy R, et al. Transcriptional regulation of the base excision repair pathway by BRCA1. J Biol Chem 2010, 285:19092-19105.
171. Pellegrini L, Yu DS, Lo T, et al. Insights into DNA recombination from the structure of a RAD51-BRCA2 complex. Nature 2002, 420:287-293.
172. Yang H, Jeffrey PD, Miller J, et al. BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure. Science 2002, 297:1837-1848.
173. Lord CJ, Ashworth A The DNA damage response and cancer therapy. Nature 2012, 481:287-294.
174. Hartman AR, Ford JM BRCA1 and p53: compensatory roles in DNA repair. J Mol Med 2003.
175. Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005, 434:913-917.
176. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005, 434:917-921.
177. Durkacz BW, Omidiji O, Gray DA, Shall S (ADP-ribose)n participates in DNA excision repair. Nature 1980, 283:593-596.
178. Telli ML, Ford JM PARP inhibitors in breast cancer. Clinical advances in hematology & oncology: H&O 2010, 8:629-635.
179. Javle M, Curtin NJ The role of PARP in DNA repair and its therapeutic exploitation. British journal of cancer 2011, 105:1114-1122.
180. Lucchesi JC Synthetic lethality and semi-lethality among functionally related mutants of Drosophila melanfgaster. Genetics 1968, 59:37-44.
181. Hartwell LH, Szankasi P, Roberts CJ, et al. Integrating genetic approaches into the discovery of anticancer drugs. Science 1997, 278:1064-1068.
182. Kaelin WG The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 2005, 5:689-698.
183. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009, 361:123-134.
184. Alter BP Cancer in Fanconi anemia, 1927-2001. Cancer 2003, 97:425-440.
185. D'Andrea AD, Grompe M The Fanconi anaemia/BRCA pathway. Nat Rev Cancer 2003, 3:23-34.
186. D'Andrea AD Susceptibility pathways in Fanconi's anemia and breast cancer. N Engl J Med 2010, 362:1909-1919.
187. Kennedy RD, D''Andrea AD DNA repair pathways in clinical practice: lessons from pediatric cancer susceptibility syndromes. J Clin Oncol 2006, 24:3799-3808.
188. Moldovan GL, D'Andrea AD To the rescue: the fanconi anemia genome stability pathway salvages replication forks. Cancer Cell 2012, 22:5-6.
189. Kim H, D'Andrea AD Regulation of DNA cross-link repair by the Fanconi anemia/BRCA pathway. Genes Dev 2012, 26:1393-1408.
190. Howlett NG, Taniguchi T, Olson S, et al. Biallelic inactivation of BRCA2 in Fanconi anemia. Science 2002, 297:606-609.
191. Kim H, Yang K, Dejsuphong D, D'Andrea AD Regulation of Rev1 by the Fanconi anemia core complex. Nat Struct Mol Biol 2012, 19:164-170.
192. Taniguchi T, Garcia-Higuera I, Xu B, et al. Convergence of the fanconi anemia and ataxia telangiectasia signaling pathways. Cell 2002, 109:459-472.